None listed
Conditions
Interventions
Drug : 1. Test Group (Tigecycline)
- After the first dose of tigecycline 100 mg (Tigacil, Pfizer Korea Pharmaceuticals) intravenously, 50 mg twice daily at 12-hour intervals for 5 days
- If fever i
Sponsors
Inha University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Among inpatients 19 years of age or older who have a fever of 37.5°C or higher (tympanic temperature measurement standard), rash, or crusts suspected of tsutsugamushi, who voluntarily decided to participate in the study 2. Patient is diagnosed with tsutsugamushi disease by department of infectious disease specialist 3. After hearing and fully understanding the detailed explanation of this clinical study, a person who voluntarily decides to participate and agrees in writing to abide by the precautions
Exclusion criteria
Exclusion criteria: 1. Exclusion complications: Patients with severe complications such as respiratory distress pneumonia, encephalitis (Investigator decides on final exclusion) 2. Chronic renal dysfunction patient 3. Patient with a body weight of <45kg 4. Immunocompromised patients: Administration of glucocorticoid and/or immunoglobulins for long-term 5. Pregnant woman 6. For both male and female patients, the patient and his or her partner of childbearing potential who does not agree to use a highly effective or medically acceptable methods of contraception during the course of the study and for 3 months following discontinuation of study drug as specified below: * IUD (Intrauterinedevice), Barrier contraception that must include spermicide (for women's contraceptive diaphragm/vaginal sponge sponge/cervical cap) and double-blocking method (excluding simultaneous use of male and female condoms) with male condom use, infertility Procedures (vasectomy, vasectomy, tubal ligation, etc.) 7. Unable to take medications by mouth 8. Received any anti-rickettsia drug (including rifampin, chloramphenicol, macrolide, quinolone and tetracycline) 9. Patients with shock or multiple organ failure that require vasopressors/vasoconstrictors, patients with reduced consciousness, patients with respiratory failure that require mechanical ventilation, patients with renal failure requiring hemodialysis 10. Diagnosed with a disease other than tsutsugamushi
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time from antibiotic administration to 37.3°C or lower and maintained for more than 48 hours without fever-reducing drugs | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) To assess the antipyretic on the third day of treatment (treatment success / failure) (2) Whether or not Tsutsugamushi disease recurs after 4 weeks (second outpatient visit) from participating in the study | — |
Countries
Korea, Republic of
Contacts
Public ContactHyeJin Lee
Inha University Hospital
Outcome results
None listed